Share Price and Basic Stock Data
Last Updated: December 24, 2025, 2:33 am
| PEG Ratio | -9.58 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Morepen Laboratories Ltd operates in the pharmaceuticals sector, where it reported a current market price of ₹42.3 and a market capitalization of ₹2,315 Cr. The company’s sales have demonstrated a fluctuating yet upward trend, with total sales for FY 2025 standing at ₹1,812 Cr, compared to ₹1,418 Cr in FY 2023. Quarterly sales figures also reflect growth, with the latest quarter (Jun 2025) reporting sales of ₹425 Cr, up from ₹401 Cr in Jun 2023. The trailing twelve months (TTM) revenue was recorded at ₹1,755 Cr, indicating a consistent performance in revenue generation. This growth trajectory showcases the company’s ability to adapt to market demands and expands its presence within the pharmaceutical industry, supported by a rising trend in operational revenue per share, which stood at ₹33.06 for FY 2025. The company’s resilience in sales performance underscores its strategic positioning in the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Morepen Laboratories Ltd recorded a net profit of ₹118 Cr for FY 2025, a significant recovery from a net profit of ₹39 Cr in FY 2023, indicating an impressive growth in profitability. The operating profit margin (OPM) for FY 2025 rose to 10.62%, compared to 6% in the current financial year, showcasing improved operational efficiency. The company’s return on equity (ROE) stood at 10.20%, and return on capital employed (ROCE) was reported at 12.79%, both of which are indicative of effective capital utilization relative to its earnings. Furthermore, the interest coverage ratio (ICR) of 23.07x highlights the company’s strong ability to meet its interest obligations, reflecting a robust financial position. However, the operating profit margins have fluctuated in recent quarters, with the latest margin reported at 6% for Jun 2025, suggesting potential challenges in maintaining profitability amid rising expenses.
Balance Sheet Strength and Financial Ratios
The balance sheet of Morepen Laboratories Ltd exhibits a strong financial foundation, with total reserves increasing to ₹1,087 Cr as of Sep 2025, up from ₹651 Cr in FY 2023. The total borrowings stood at ₹158 Cr, indicating a low debt level and a total debt-to-equity ratio of 0.06, which is favorable compared to industry standards. The company’s current ratio of 2.32x and quick ratio of 1.72x demonstrate solid liquidity, allowing it to meet short-term liabilities effectively. The book value per share increased to ₹21.10 in FY 2025, reflecting a growing underlying asset base. However, the cash conversion cycle (CCC) of 45 days, while manageable, indicates areas for improvement in inventory management and receivables collection. Overall, the balance sheet metrics portray a company with strong financial health, capable of sustaining its operations and growth trajectory.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Morepen Laboratories Ltd illustrates a diversified ownership structure, with promoters holding 35.66% of the shares, while public shareholders account for 61.22%. Foreign Institutional Investors (FIIs) have a stake of 1.62%, and Domestic Institutional Investors (DIIs) hold 1.49%. The number of shareholders increased to 4,61,853 as of Sep 2025, reflecting growing retail interest and confidence in the company’s prospects. The gradual decline in promoter shareholding from 38.22% in Mar 2023 to 35.66% in Sep 2025 could raise questions regarding long-term commitment; however, the stable public holding indicates strong market support. Additionally, the absence of any government holding suggests a free market environment, which may appeal to potential investors seeking transparency and independence in corporate governance.
Outlook, Risks, and Final Insight
Looking ahead, Morepen Laboratories Ltd is well-positioned for growth, supported by its solid revenue generation and improving profitability metrics. However, risks remain, including potential fluctuations in raw material costs and regulatory challenges within the pharmaceutical sector. The company’s ability to sustain its growth will depend on effective cost management and maintaining operational efficiency. Furthermore, the increasing competition in the pharmaceutical industry could impact market share. Should the company successfully navigate these challenges and capitalize on its operational strengths, it could enhance shareholder value significantly. Conversely, failure to address these risks may hinder growth prospects. Overall, Morepen Laboratories Ltd presents a cautiously optimistic outlook, with the potential for sustained performance if it manages its operational challenges effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 138 Cr. | 110 | 231/84.3 | 30.5 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,435 Cr. | 408 | 479/192 | 91.8 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.2 Cr. | 47.5 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 49.8 Cr. | 34.0 | 34.7/17.0 | 119 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,303.43 Cr | 1,155.94 | 53.33 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 302 | 403 | 348 | 364 | 401 | 422 | 445 | 423 | 455 | 438 | 453 | 466 | 425 |
| Expenses | 288 | 374 | 328 | 348 | 375 | 388 | 394 | 375 | 404 | 394 | 417 | 424 | 401 |
| Operating Profit | 15 | 29 | 21 | 16 | 26 | 34 | 51 | 48 | 52 | 44 | 36 | 42 | 24 |
| OPM % | 5% | 7% | 6% | 4% | 7% | 8% | 11% | 11% | 11% | 10% | 8% | 9% | 6% |
| Other Income | 1 | 1 | 1 | 3 | 2 | 3 | 4 | 4 | 3 | 5 | 5 | 5 | 4 |
| Interest | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 5 | 4 |
| Depreciation | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 10 | 6 | 2 | 5 | 16 | 9 |
| Profit before tax | 8 | 22 | 14 | 11 | 21 | 29 | 44 | 42 | 48 | 46 | 35 | 26 | 16 |
| Tax % | 32% | 29% | 36% | 26% | 29% | 26% | 27% | 32% | 25% | 24% | 24% | 21% | 26% |
| Net Profit | 6 | 16 | 9 | 8 | 15 | 21 | 32 | 29 | 36 | 35 | 27 | 20 | 11 |
| EPS in Rs | 0.11 | 0.31 | 0.18 | 0.16 | 0.29 | 0.42 | 0.63 | 0.55 | 0.71 | 0.64 | 0.49 | 0.37 | 0.20 |
Last Updated: August 20, 2025, 6:50 am
Below is a detailed analysis of the quarterly data for Morepen Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 425.00 Cr.. The value appears to be declining and may need further review. It has decreased from 466.00 Cr. (Mar 2025) to 425.00 Cr., marking a decrease of 41.00 Cr..
- For Expenses, as of Jun 2025, the value is 401.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 424.00 Cr. (Mar 2025) to 401.00 Cr., marking a decrease of 23.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 42.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 18.00 Cr..
- For OPM %, as of Jun 2025, the value is 6.00%. The value appears to be declining and may need further review. It has decreased from 9.00% (Mar 2025) to 6.00%, marking a decrease of 3.00%.
- For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 9.00 Cr., marking a decrease of 7.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 10.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Mar 2025) to 26.00%, marking an increase of 5.00%.
- For Net Profit, as of Jun 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 20.00 Cr. (Mar 2025) to 11.00 Cr., marking a decrease of 9.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.20. The value appears to be declining and may need further review. It has decreased from 0.37 (Mar 2025) to 0.20, marking a decrease of 0.17.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:57 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 367 | 401 | 485 | 595 | 607 | 769 | 853 | 1,188 | 1,547 | 1,418 | 1,690 | 1,812 | 1,755 |
| Expenses | 318 | 352 | 424 | 534 | 542 | 701 | 785 | 1,070 | 1,410 | 1,338 | 1,532 | 1,638 | 1,622 |
| Operating Profit | 49 | 48 | 62 | 61 | 65 | 68 | 69 | 119 | 137 | 80 | 159 | 174 | 133 |
| OPM % | 13% | 12% | 13% | 10% | 11% | 9% | 8% | 10% | 9% | 6% | 9% | 10% | 8% |
| Other Income | 4 | 1 | -3 | 4 | 4 | 4 | 9 | 12 | 10 | 6 | 14 | 18 | 45 |
| Interest | 10 | 9 | 10 | 8 | 4 | 2 | 2 | 2 | -7 | 2 | 4 | 8 | 14 |
| Depreciation | 46 | 39 | 35 | 34 | 34 | 40 | 37 | 30 | 28 | 28 | 33 | 29 | 42 |
| Profit before tax | -3 | 2 | 13 | 24 | 30 | 29 | 39 | 99 | 127 | 56 | 135 | 155 | 122 |
| Tax % | 0% | 6% | -1% | 0% | 0% | 1% | 14% | 1% | 20% | 31% | 29% | 24% | |
| Net Profit | -3 | 2 | 13 | 24 | 30 | 29 | 34 | 97 | 102 | 39 | 97 | 118 | 99 |
| EPS in Rs | -0.06 | 0.05 | 0.28 | 0.53 | 0.66 | 0.64 | 0.75 | 2.16 | 2.13 | 0.76 | 1.88 | 2.15 | 1.81 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 166.67% | 550.00% | 84.62% | 25.00% | -3.33% | 17.24% | 185.29% | 5.15% | -61.76% | 148.72% | 21.65% |
| Change in YoY Net Profit Growth (%) | 0.00% | 383.33% | -465.38% | -59.62% | -28.33% | 20.57% | 168.05% | -180.14% | -66.92% | 210.48% | -127.07% |
Morepen Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: December 4, 2025, 1:40 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 96 | 102 | 102 | 110 | 110 |
| Reserves | 88 | 78 | 91 | 106 | 136 | 163 | 194 | 335 | 483 | 651 | 745 | 1,047 | 1,087 |
| Borrowings | 209 | 201 | 187 | 169 | 134 | 132 | 133 | 17 | 19 | 25 | 29 | 105 | 158 |
| Other Liabilities | 103 | 121 | 156 | 173 | 226 | 230 | 246 | 416 | 473 | 332 | 417 | 517 | 381 |
| Total Liabilities | 490 | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,736 |
| Fixed Assets | 368 | 322 | 297 | 272 | 264 | 236 | 216 | 225 | 252 | 267 | 307 | 489 | 471 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 14 | 17 | 24 | 28 | 26 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 85 | 136 |
| Other Assets | 121 | 167 | 227 | 266 | 321 | 379 | 446 | 631 | 804 | 827 | 960 | 1,176 | 1,104 |
| Total Assets | 490 | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,736 |
Below is a detailed analysis of the balance sheet data for Morepen Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 110.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 110.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,087.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,047.00 Cr. (Mar 2025) to 1,087.00 Cr., marking an increase of 40.00 Cr..
- For Borrowings, as of Sep 2025, the value is 158.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 105.00 Cr. (Mar 2025) to 158.00 Cr., marking an increase of 53.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 381.00 Cr.. The value appears to be improving (decreasing). It has decreased from 517.00 Cr. (Mar 2025) to 381.00 Cr., marking a decrease of 136.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,736.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,778.00 Cr. (Mar 2025) to 1,736.00 Cr., marking a decrease of 42.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 471.00 Cr.. The value appears to be declining and may need further review. It has decreased from 489.00 Cr. (Mar 2025) to 471.00 Cr., marking a decrease of 18.00 Cr..
- For CWIP, as of Sep 2025, the value is 26.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 26.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 136.00 Cr.. The value appears strong and on an upward trend. It has increased from 85.00 Cr. (Mar 2025) to 136.00 Cr., marking an increase of 51.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,104.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,176.00 Cr. (Mar 2025) to 1,104.00 Cr., marking a decrease of 72.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,736.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,778.00 Cr. (Mar 2025) to 1,736.00 Cr., marking a decrease of 42.00 Cr..
Notably, the Reserves (1,087.00 Cr.) exceed the Borrowings (158.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -160.00 | -153.00 | -125.00 | -108.00 | -69.00 | -64.00 | -64.00 | 102.00 | 118.00 | 55.00 | 130.00 | 69.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 42 | 51 | 66 | 57 | 73 | 64 | 59 | 56 | 59 | 68 | 70 | 65 |
| Inventory Days | 56 | 55 | 51 | 65 | 76 | 69 | 91 | 82 | 96 | 87 | 85 | 94 |
| Days Payable | 116 | 126 | 140 | 125 | 173 | 124 | 113 | 98 | 90 | 87 | 101 | 114 |
| Cash Conversion Cycle | -17 | -20 | -23 | -3 | -24 | 9 | 37 | 40 | 65 | 69 | 54 | 45 |
| Working Capital Days | -21 | -20 | -10 | -86 | -62 | -34 | -8 | 17 | 55 | 98 | 94 | 107 |
| ROCE % | 1% | 3% | 8% | 9% | 9% | 8% | 10% | 23% | 23% | 8% | 17% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | 4,401 | 0.16 | 0.02 | 4,401 | 2025-04-22 16:00:16 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 2.20 | 1.88 | 0.77 | 2.26 | 2.16 |
| Diluted EPS (Rs.) | 2.20 | 1.88 | 0.77 | 1.96 | 2.16 |
| Cash EPS (Rs.) | 2.68 | 2.54 | 1.30 | 2.71 | 2.83 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 21.10 | 16.58 | 14.72 | 12.10 | 9.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 21.10 | 16.58 | 14.72 | 12.10 | 9.43 |
| Revenue From Operations / Share (Rs.) | 33.06 | 33.07 | 27.73 | 32.37 | 26.41 |
| PBDIT / Share (Rs.) | 3.51 | 3.38 | 1.68 | 3.08 | 2.90 |
| PBIT / Share (Rs.) | 2.98 | 2.72 | 1.13 | 2.50 | 2.23 |
| PBT / Share (Rs.) | 2.83 | 2.65 | 1.09 | 2.65 | 2.19 |
| Net Profit / Share (Rs.) | 2.15 | 1.89 | 0.75 | 2.13 | 2.16 |
| NP After MI And SOA / Share (Rs.) | 2.15 | 1.88 | 0.75 | 2.13 | 2.16 |
| PBDIT Margin (%) | 10.62 | 10.21 | 6.04 | 9.50 | 10.99 |
| PBIT Margin (%) | 9.02 | 8.23 | 4.07 | 7.71 | 8.44 |
| PBT Margin (%) | 8.56 | 8.01 | 3.93 | 8.19 | 8.29 |
| Net Profit Margin (%) | 6.51 | 5.71 | 2.72 | 6.57 | 8.17 |
| NP After MI And SOA Margin (%) | 6.51 | 5.68 | 2.72 | 6.57 | 8.17 |
| Return on Networth / Equity (%) | 10.20 | 11.34 | 5.13 | 17.57 | 22.85 |
| Return on Capital Employeed (%) | 12.79 | 15.61 | 7.31 | 19.44 | 22.07 |
| Return On Assets (%) | 6.63 | 7.43 | 3.48 | 9.50 | 11.31 |
| Long Term Debt / Equity (X) | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.06 | 0.03 | 0.03 | 0.03 | 0.03 |
| Asset Turnover Ratio (%) | 1.18 | 1.41 | 1.30 | 1.60 | 1.47 |
| Current Ratio (X) | 2.32 | 2.21 | 2.35 | 1.61 | 1.30 |
| Quick Ratio (X) | 1.72 | 1.59 | 1.64 | 1.00 | 0.87 |
| Inventory Turnover Ratio (X) | 6.60 | 3.70 | 3.10 | 3.53 | 4.01 |
| Interest Coverage Ratio (X) | 23.07 | 46.52 | 43.25 | -19.96 | 73.02 |
| Interest Coverage Ratio (Post Tax) (X) | 15.15 | 27.04 | 20.53 | -12.81 | 55.29 |
| Enterprise Value (Cr.) | 2682.56 | 2126.72 | 1280.99 | 1720.86 | 1393.88 |
| EV / Net Operating Revenue (X) | 1.48 | 1.26 | 0.90 | 1.11 | 1.17 |
| EV / EBITDA (X) | 13.94 | 12.32 | 14.95 | 11.71 | 10.67 |
| MarketCap / Net Operating Revenue (X) | 1.45 | 1.27 | 0.92 | 1.13 | 1.22 |
| Price / BV (X) | 2.27 | 2.54 | 1.74 | 3.02 | 3.40 |
| Price / Net Operating Revenue (X) | 1.45 | 1.27 | 0.92 | 1.13 | 1.22 |
| EarningsYield | 0.04 | 0.04 | 0.02 | 0.05 | 0.06 |
After reviewing the key financial ratios for Morepen Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 5. It has increased from 1.88 (Mar 24) to 2.20, marking an increase of 0.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 5. It has increased from 1.88 (Mar 24) to 2.20, marking an increase of 0.32.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.68. This value is below the healthy minimum of 3. It has increased from 2.54 (Mar 24) to 2.68, marking an increase of 0.14.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 21.10. It has increased from 16.58 (Mar 24) to 21.10, marking an increase of 4.52.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 21.10. It has increased from 16.58 (Mar 24) to 21.10, marking an increase of 4.52.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 33.06. It has decreased from 33.07 (Mar 24) to 33.06, marking a decrease of 0.01.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.51. This value is within the healthy range. It has increased from 3.38 (Mar 24) to 3.51, marking an increase of 0.13.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.98. This value is within the healthy range. It has increased from 2.72 (Mar 24) to 2.98, marking an increase of 0.26.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.83. This value is within the healthy range. It has increased from 2.65 (Mar 24) to 2.83, marking an increase of 0.18.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.89 (Mar 24) to 2.15, marking an increase of 0.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.88 (Mar 24) to 2.15, marking an increase of 0.27.
- For PBDIT Margin (%), as of Mar 25, the value is 10.62. This value is within the healthy range. It has increased from 10.21 (Mar 24) to 10.62, marking an increase of 0.41.
- For PBIT Margin (%), as of Mar 25, the value is 9.02. This value is below the healthy minimum of 10. It has increased from 8.23 (Mar 24) to 9.02, marking an increase of 0.79.
- For PBT Margin (%), as of Mar 25, the value is 8.56. This value is below the healthy minimum of 10. It has increased from 8.01 (Mar 24) to 8.56, marking an increase of 0.55.
- For Net Profit Margin (%), as of Mar 25, the value is 6.51. This value is within the healthy range. It has increased from 5.71 (Mar 24) to 6.51, marking an increase of 0.80.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.51. This value is below the healthy minimum of 8. It has increased from 5.68 (Mar 24) to 6.51, marking an increase of 0.83.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.20. This value is below the healthy minimum of 15. It has decreased from 11.34 (Mar 24) to 10.20, marking a decrease of 1.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.79. This value is within the healthy range. It has decreased from 15.61 (Mar 24) to 12.79, marking a decrease of 2.82.
- For Return On Assets (%), as of Mar 25, the value is 6.63. This value is within the healthy range. It has decreased from 7.43 (Mar 24) to 6.63, marking a decrease of 0.80.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.06, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.18. It has decreased from 1.41 (Mar 24) to 1.18, marking a decrease of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 2.32. This value is within the healthy range. It has increased from 2.21 (Mar 24) to 2.32, marking an increase of 0.11.
- For Quick Ratio (X), as of Mar 25, the value is 1.72. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 1.72, marking an increase of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.60. This value is within the healthy range. It has increased from 3.70 (Mar 24) to 6.60, marking an increase of 2.90.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 23.07. This value is within the healthy range. It has decreased from 46.52 (Mar 24) to 23.07, marking a decrease of 23.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 15.15. This value is within the healthy range. It has decreased from 27.04 (Mar 24) to 15.15, marking a decrease of 11.89.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,682.56. It has increased from 2,126.72 (Mar 24) to 2,682.56, marking an increase of 555.84.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 1.48, marking an increase of 0.22.
- For EV / EBITDA (X), as of Mar 25, the value is 13.94. This value is within the healthy range. It has increased from 12.32 (Mar 24) to 13.94, marking an increase of 1.62.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 1.45, marking an increase of 0.18.
- For Price / BV (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 2.27, marking a decrease of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 1.45, marking an increase of 0.18.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Morepen Laboratories Ltd:
- Net Profit Margin: 6.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.79% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.2% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 15.15
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.72
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30.7 (Industry average Stock P/E: 53.33)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Morepen Village, Solan District Himachal Pradesh 173205 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sushil Suri | Chairman & Managing Director |
| Mr. Sanjay Suri | Whole Time Director |
| Mr. Praveen Kumar Dutt | Independent Director |
| Dr.(Mrs.) Savita | Independent Director |
| Mr. Ranjit Khattar | Independent Director |
| Mr. Sharad Jain | Independent Director |
FAQ
What is the intrinsic value of Morepen Laboratories Ltd?
Morepen Laboratories Ltd's intrinsic value (as of 23 December 2025) is 63.48 which is 50.07% higher the current market price of 42.30, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 2,316 Cr. market cap, FY2025-2026 high/low of 80.7/38.4, reserves of ₹1,087 Cr, and liabilities of 1,736 Cr.
What is the Market Cap of Morepen Laboratories Ltd?
The Market Cap of Morepen Laboratories Ltd is 2,316 Cr..
What is the current Stock Price of Morepen Laboratories Ltd as on 23 December 2025?
The current stock price of Morepen Laboratories Ltd as on 23 December 2025 is 42.3.
What is the High / Low of Morepen Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Morepen Laboratories Ltd stocks is 80.7/38.4.
What is the Stock P/E of Morepen Laboratories Ltd?
The Stock P/E of Morepen Laboratories Ltd is 30.7.
What is the Book Value of Morepen Laboratories Ltd?
The Book Value of Morepen Laboratories Ltd is 21.8.
What is the Dividend Yield of Morepen Laboratories Ltd?
The Dividend Yield of Morepen Laboratories Ltd is 0.47 %.
What is the ROCE of Morepen Laboratories Ltd?
The ROCE of Morepen Laboratories Ltd is 15.1 %.
What is the ROE of Morepen Laboratories Ltd?
The ROE of Morepen Laboratories Ltd is 11.8 %.
What is the Face Value of Morepen Laboratories Ltd?
The Face Value of Morepen Laboratories Ltd is 2.00.